Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors

Summary

This study is a single arm, pilot study of pazopanib in patient with FGFR2 amplification Refractory solid tumor and/or specific sensitivity to pazopanib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy. To investigate the efficacy and safety of pazopanib in patient with Refractory solid tumor.

Timeline

Start

2016-05

Primary completion

2018-01-16

Completion

2020-02-13

Drugs

Indications